Search Medical Condition
Please enter condition
Please choose location from dropdown

Anderson, South Carolina Clinical Trials

A listing of Anderson, South Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (89) clinical trials

Evaluation of Major Cardiovascular Events in Patients With or at High Risk for Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

Phase

0.0 miles

Learn More »

Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)

This is a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Once randomized, subjects will take the initial dose of study drug at the study site on ...

Phase

0.0 miles

Learn More »

Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)

This is an open-label study to evaluate the safety of continued therapy with oral treprostinil in subjects who have completed Study TDE-HF-301. This study will provide long-term, open-label data regarding the effect of continued long-term oral treprostinil therapy for the treatment of pulmonary hypertension (PH) associated with heart failure with ...

Phase

0.0 miles

Learn More »

ADAPT - A Patient Registry of the Real-world Use of Orenitram

This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation

Phase N/A

0.0 miles

Learn More »

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.

Phase

0.0 miles

Learn More »

RESOLUTE ONYX Post-Approval Study

To observe the continued performance of the Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population.

Phase N/A

0.0 miles

Learn More »

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

This is a study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease. The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these ...

Phase

0.0 miles

Learn More »

QP ExCELs: MultiPole Pacing (MPP) Sub-Study

The objective of this MultiPole Pacing (MPP) sub-study of the QP ExCELs study is to demonstrate that the MPP feature is effective by converting a percentage of cardiac resynchronization therapy (CRT) non-responders to responders. The MPP sub-study is a single-arm, multi-center, prospective trial within the ongoing QP ExCELs study (NCT02290028).

Phase N/A

0.0 miles

Learn More »

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme Drug Coated Coronary Stent in Patients With Coronary Disease

The primary objective of this trial is to compare the safety and efficacy of the SINOMED BuMA Supreme biodegradable coronary stent in patients with up to 3 coronary lesions to either the XIENCE or Promus durable polymer coronary stents. This prospective, global, multi-center, randomized 2:1, single blind study will enroll ...

Phase N/A

0.0 miles

Learn More »

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Patients With Type 2 Diabetes Moderate Impairment of Kidney Function and Inadequate Blood Sugar Control

The study duration is up to 60 weeks including 4 weeks prior to randomization, 52 weeks of randomized treatment, and a visit 4 weeks after completion of the randomized treatment period.

Phase

0.0 miles

Learn More »